AZ Brushes Off Vaccine Criticism, Awaits US Readout
WHO Endorsement Counters Fears
While fast-developing news on COVID-19 is grabbing the headlines, oncology will continue to drive growth in 2021.
You may also be interested in...
The agreement focuses on respiratory viruses, especially influenza, and includes a $225m upfront payment plus an increase in GSK’s equity investment in Vir.
Some analysts are suggesting that AstraZeneca is getting hold of a "scarce and high-quality asset" in Alexion for a very reasonable price and shareholders could demand more than the $175 per share offer on the table.
A rush of additional orders from countries around the world has boosted the company’s prospects, and fueled its ambitions beyond COVID-19.